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ATP release in human kidney cortex and its mitogenic effects There is convincing evidence that overactivity of the
in visceral glomerular epithelial cells. sympathetic nervous system plays a dominant role in
Background. In chronic renal failure the sympathetic ner- renal hypertensive disease [1–3]. The kidneys possess
vous system is activated. Sympathetic cotransmitters released
mechanoreceptors and chemoreceptors that are stimu-within the kidney may contribute to the progression of renal
lated in damaged kidneys [4]. These afferent sensorydisease through receptor-mediated proliferative mechanisms.
signals travel to the central nervous system leading toMethods. In human renal cortex electrical stimulation induced
adenosine 5-triphosphate (ATP; luciferin-luciferase-assay) and enhanced efferent sympathetic activity [5]. It is our hy-
norepinephrine (HPLC) release was measured. ATP release also pothesis that sympathetic overactivity of renal nerves
was induced by 1- and 2-adrenergic agonists. [3H]-thymidine contributes to progression of renal disease by a direct
uptake was tested in human visceral glomerular epithelial cells
receptor-mediated stimulation of cell growth [2]. This is(vGEC) and mitogen-activated protein kinase (MAPK42/44) acti-
based on recent observations in a model of chronic renalvation in vGEC and kidney cortex. The involved P2-receptors
failure characterized by sympathetic overactivity [6].were characterized pharmacologically and by RT-PCR.
Results. Sympathetic nerve stimulation and -adrenergic ag- Treatment of subtotally nephrectomized rats with the
onists induced release of ATP from human kidney cortex. sympatholytic drug moxonidine, known to inhibit neuro-
Seventy-five percent of the ATP released originated from non- transmitter release within the kidney [7], or a -blockerneuronal sources, mainly through activation of 2-adrenergic [8] ameliorated proteinuria and reduced glomerular dam-receptors. ATP (1 to 100 mol/L) and related nucleotides (1 to
age independent from blood pressure effects. There is100 mol/L) increased [3H]-thymidine uptake. The adenine nu-
experimental evidence that norepinephrine is not thecleotides ATP, ATPS, ADP and ADPS were about equally
potent. UTP, UDP and ,-methylene ATP had no effect. only renal neurotransmitter. In kidneys of rats and hu-
ATP, ADPS but not,-methylene ATP activated MAPK42/44. mans ATP seems to be released as a cotransmitter of
ATP induced MAPK42/44 activation, and [3H]-thymidine uptake norepinephrine [9–13] and has been shown to act as mito-was abolished in the presence of the MAPK inhibitor PD 98059
genic signaling molecule in rat mesangial [14] and human(100 mol/L). mRNA for P2X4,5,6,7 and P2Y1,2,4,6,11 were detected
smooth muscle cells [15]. Thus, besides norepinephrinein human vGEC by RT-PCR.
Conclusions. In human renal cortex, adrenergic stimulation itself, the cotransmitter ATP is a prime candidate to be
releases ATP from neuronal and non-neuronal sources. ATP involved in progression of chronic renal disease in the
has mitogenic effects in vGEC and therefore the potential to presence of sympathetic overactivity. The present study
contribute to progression in chronic renal disease. The pattern tested the hypothesis that sympathetic stimulation leadsof purinoceptor agonist effects on DNA synthesis together with
to ATP release in the human kidney and that ATP pos-the mRNA expression suggests a major contribution of a P2Y1-
sesses mitogenic effects in human glomerular epitheliallike receptor.
cells (vGEC). We chose this cell type as a model because
it is involved in progression of chronic renal failure [16].
A portion of this study was presented at the 4th Annual
Meeting of the European Council for Blood Pressure and
Cardiovascular Research in Nordwijkerhout (abstract;
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undergoing nephrectomy for renal cell carcinoma. Only was then aspirated, the cells washed three times with
phosphate buffer and for DNA precipitation twice withmacroscopic intact renal cortex tissue was used for cell
ice-cold 10% trichloroacetic acid (TCA). The fixed cellu-preparation. Renal cortical slices were minced, pushed,
lar material was solubilized in 1 mL 0.5 mol/L NaOHand rinsed through a serial of stainless steel sieves of
for two hours and then mixed with 10 mL scintillationdifferent pore sizes of 40, 80 and finally 120 mesh. Glo-
fluid (Canberra Packard, Ultima-Gold) to measure themeruli retained by the 120 mesh sieves were collected
amount of radioactivity present in the TCA insolublein tubes and centrifuged at 1750  g for eight minutes,
fraction. Data are expressed as the mean of radioactivityand suspended in RPMI medium containing 20% fetal
present in the four wells with identical concentration.calf serum (FCS) with supplements (1% non-essential
amino acids; 5 mmol/L HEPES; 1 mmol/L Na-pyruvate,
RNA extraction and reverse transcription-polymerase100 U/mL penicillin; 100 g/mL streptomycin; Biochrom,
chain reaction of P2X and P2Y receptorsBerlin, Germany; 1% insulin-transferrin-selenite supple-
RNA was gained from 2 106 cells using the RNAeasyment, Roche Biochemicals, Mannheim, Germany). Glo-
Kit (Qiagen, Hilden, Germany). For the synthesis of themeruli were then incubated at 37C. Primary cultures
first strand 2 g RNA was used in the superscript first-and subcultures were maintained at 37C in a 5% CO2
strand system (Gibco-BRL, Karlsruhe, Germany). Dueenvironment. Plates were left undisturbed for the next
to a strong signal for P2X5-receptors, only 0.2 g RNAfive to seven days to facilitate primary outgrowth of
was used for this subtype. The amplification was per-visceral epithelial cells (vGEC) from glomeruli. Then,
formed in a volume of 50 L with 10% of the first strandthe plated cells were trypsinized and passaged. All cells
cDNA with AmpliTaq Gold (Applied Biosystems, Weit-were studied within the first twelve passages.
erstadt, Germany), five minutes at 95C, one minute at
95C, one minute at 55C, one minute at 72C, 35 cycles,Cell identification of vGEC
and for termination eight minutes at 72C. Ten microli-Cell purity was assessed by the peroxidase anti peroxi-
ters of the reaction were then analyzed on a 1.5% agarosedase (PAP) staining from Dako Corp. (Hamburg, Ger-
gel. Primers used were:many) following the manufacturer’s instructions. Pri-
mary antihuman antibodies used were mouse anti-factor
P2Y1: TGCCAGCCCTGATCTTCTACTACT, ATACVIII-related antigen, mouse anti-cytokeratin, mouse anti-
GTGGCATAAACCCTGTCATT
vimentin, mouse anti-desmin, mouse anti-smooth muscle P2Y2: GCCGGGGCCGTGTGGGTGTT, CGGGTGAactin (all from Dako) and rabbit anti-Wilm’s tumor anti- CGTGGAATGGCAGGAA
gen (WT-1; Santa Cruz Biotechnology, Santa Cruz, CA, P2Y4: GGGATGCAACGGCCACCTACA, GCACGAUSA). Secondary antibodies were mouse anti-rabbit IgG AGCAGACAGCAAAGACAG
and rabbit anti-mouse IgG (both 1:100; Dako). vGEC used P2Y6: CCCTGCTGGCCTGCTACTGTCTCC, TTCTCfor experiments were cytokeratin- and WT-1–positive, CGCATGGTTTGGGGTTGGT
whereas mesangial and renal smooth muscle cells were P2Y11: CCCCCGCTGGCCGCCTACCTCTTA, GCCC
cytokeratin-positive but showed no staining for WT-1. AACCCCGCCAGCACCAG
P2Y12: CTCTGTTGTCATCTGGGCATTCAT, GGTTAnalysis of mitogenic effects
TGGCTCAGGGTGTAAGGA
All experiments to study mitogenic effects were done P2X1: CTTTCCACGCTTCAAGGTCAACA, GCCAC
under growth-arrested conditions. vGEC cells were plated CCCAAAGATGCCA AT
at a density of 30,000 cells/well in 24-well plates and grown P2X2: ACAAAGTGTGGGACGTGGAGGA, GGCA
to 80% confluence in REBM (renal epithelial cell basis AACCTGAAGTTGTAGCCTGA
medium; Cellsystems, St. Katharinen, Germany) plus sup- P2X3: TCTGTGCTCCGGACCTGTGAGAT, AAGC
plement (REGM, renal epithelial cell growth medium; GGATGCCAAAAGCCTTCA
Cellsystems) before they were placed in growth arrest P2X4: CCTTCTGCCCCATATTCCGTCT, GTTGATC
medium (RPMI medium supplemented with 0.5% FCS; ATAGTGGGGATGATGTCA
5 g/mL insulin; Sigma, Deisendorf, Germany; and 100 P2X5a/b: GAGTGCTGTCATCACCAAAGTCAA, CCA
U/mL penicillin/100 g/mL streptomycin) for 72 hours GTCGGAAGATGGGGCAGTA
to decrease proliferation. P2X6: CCTGTGAGATCTGGAGTTGGTGC, GTGTC
CAGGTCACAATCCCAGT
Determination of DNA-synthesis P2X7: CGACTTCCCCGGCCACAACTA, TGCCAA
DNA synthesis was measured using [3H]-thymidine AAACCAGGATGTCAAAAC
incorporation. All studied substances were added to rest-
Determination of MAPK42/44 activationing cells (4 wells for each concentration) and were pres-
ent for 24 hours. The cells were incubated with [3H]-thy- Kinetics of MAPK42/44 phosphorylation were done by
stimulation of resting vGECs plated on six-well platesmidine (1 Ci/mL) during the last six hours. The medium
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with ATP (100 mol/L) for 0, 2, 5, 10, 15 and 20 minutes. (40 mA, 1 ms duration). Drugs were applied 15 minutes
before S2. Three three-minute samples of the superfu-For experiments using the mitogen-activated protein
(MAP) kinase (MAPK)/extracellular signal-regulated sate were collected on ice by using a fraction collector,
and were used for the simultaneous determination ofprotein kinase (ERK) kinase (MEK) inhibitor PD-98059
(New England BioLabs; Beverly, MA, USA), cells were norepinephrine and ATP as previously described in de-
tail [10]. Briefly, aliquots (1 mL) of the three three-incubated for 30 minutes at 37C in growth arresting
medium that contained the inhibitor before the addition minute samples were immediately separated after each
experiment and kept at 20C until determination ofof agonists. After treatment, medium was aspirated and
cells were solubilized in 200 L 2 Laemmli sample ATP levels, which were assessed by the luciferin-lucifer-
ase technique using a LB 953 luminometer (Bertholdbuffer with 200 mmol/L dithiothreitol (DTT) followed
by boiling for five minutes. Lysates were sonicated, and Systems, Germany). The remaining part of the fractions
received 167 L of 1 mol/L HCl, 13.3 L of 0.067 mol/Lproteins were separated on 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gels. ethylenediaminetetraacetic acid (EDTA) and 3.3 L of
1 mol/L NaSO4 to prevent norepinephrine degradation.The proteins were electrophoretically transferred to ni-
trocellulose in buffer containing 25 mmol/L Tris, 192 Norepinephrine content was concentrated by adsorbing
onto alumina and resolving in 250 L 0.1 mol/L HClO4mmol/L glycine, 20% methanol, and 0.02% SDS. The
nitrocellulose was blocked with 5% nonfat dry milk in and determined by high-pressure liquid chromatography
with electrochemical detection (HPLC-ECD; Waters,20 mmol/L Tris, pH 7.4, 150 mmol/L NaCl, and 0.01%
Tween 20. The membranes were probed either with a Eschborn, Germany). All values were corrected for re-
covery. The ATP release also induced was by adrenergicpolyclonal phosphotyrosyl-MAP kinase-specific antibody
(New England BioLabs), which recognizes only the tyro- agonists. In this case, there was no electrical field stimula-
tion but -adrenergic agonists were added to the perfu-sine-phosphorylated (active) form of p44 MAP ki-
nase (ERK1) and p42 MAP kinase (ERK2) or with a sion solution for one minute instead of S2. The three
respective three-minute samples of S1 were taken as aMAP kinase-specific antibody (New England BioLabs),
which recognizes the total amount of ERK1 and ERK2. reference value (control without any stimulation). When
-adrenergic antagonists were used in the latter experi-The buffer used for incubation contained 20 mmol/L
Tris, pH 7.4, 150 mmol/L NaCl, 3% bovine serum albu- ments, they were added to the perfusion solution from
30 minutes before S1 to the end of the experimentmin (BSA), and 0.01% Tween 20. The blots were then
washed in 20 mmol/L Tris, pH 7.4, 150 mmol/L NaCl, (throughout).
and 0.01% Tween 20, and bound antibody was detected
Statisticsby a horseradish peroxidase-conjugated anti-rabbit IgG
and enhanced chemiluminescence (Pierce, Rockford, IL, All data are expressed as means 	 SEM. Data were
analyzed by the unpaired Student t test. Values of P 
USA). The detection and estimation of the ratio between
activated and total protein was performed with the Ko- 0.05 were considered statistically significant.
dak Imaging System. The density ratio was used as the
quantum of MAPK42/44 activation. MAPK42/44 phosphory-
RESULTS
lation induced by electrical stimulation at 5 Hz for four
Sympathetic nerve stimulation and release of ATPminutes (40 mA, 1 ms duration) or by ATP (100 mol/L)
and norepinephrine in human cortical kidney slicesalso was measured in superfused human renal cortex.
ATP (100 mol/L) was added to the perfusion solution Electric field stimulation of human cortical kidney
slices induced concomitant release of ATP and norepi-for 10 minutes. The tissue samples were harvested imme-
diately after the stimulations and snap frozen. The exper- nephrine in S1 and S2 (Fig. 1). Upon stimulation the
slices released more ATP (total stimulation induced re-imental design of the superfused renal cortex is described
in detail below. lease in S1, 0.24 	 0.03 pmol/mg kidney cortex; N 
21) than norepinephrine (0.12 	 0.01 pmol/mg kidney
Norepinephrine and ATP release of human kidney cortex; N 21). S2 to S1 ratios for ATP and norepineph-
slices by sympathetic nerve stimulation rine were about 0.75 and set as 100% (control). When
the sodium channel blocker tetrodotoxin (1 mol/L) wasThe cortical kidney slices of about 25 mg (diameter
6.5 mm, thickness 0.3 mm) were placed into eight su- added before the second stimulation period, the ATP
and norepinephrine release was abolished (Fig. 2). Inperfusion chambers between two platinum electrodes
and were kept in a bath at a temperature of 37C [21]. the presence of complete -adrenergic blockade by a
combination of the preferential 1-adrenergic antagonistThe slices were superfused at a constant rate of 2 mL/min
with Krebs-Henseleit solution [17]. After a stabilization prazosin (3 mol/L) and the preferential 2-adrenergic
antagonist rauwolscine (1 mol/L) the stimulation inducedperiod of 60 minutes there were two periods of electric
field stimulation (S1, S2), each 20 Hz for one minute release of ATP was reduced to about 25% of control (Fig.
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triphosphate (UTP; 1 to 100 mol/L), uridine diphos-
phate (UDP; 1 to 100 mol/L; data not shown) and ,-
methylene ATP (1 to 100 mol/L) had no effect in
vGEC. BzATP (100 mol/L) and BzATP (300 mol/L)
reduced [3H]-thymidine uptake to 49 	 8.4% (N  8)
and 24.2 	 2.3% of control (N  7), respectively. The
P2-receptor antagonist suramin (30 mol/L; Fig. 5),
known to block a number of P2-subtypes, and the MAPK
inhibitor PD 98059 (100 mol/L) reduced basal (23.1% 	
2.2 of control; N  3) and ATP induced [3H]-thymidine
uptake in vGEC (Fig. 6A).
Involvement of the MAPK pathway
In human visceral glomerular epithelial cells (vGEC)
ATP (100 mol/L) and ADPS (100 mol/L) induced
a fast activation of the MAPK42/44 pathway (Figs. 6B and
7). The maximum activation of MAPK42/44 by ATP and
ADPS was observed five minutes after the addition of
these nucleotides (Fig. 7). A more than twofold increase
was still present 20 minutes after addition of the nucleo-
tides (Fig. 7). ,-Methylene-ATP (100 mol/L) did not
activate MAPK42/44 (Fig. 7). In the presence of the MAPK
inhibitor PD 98059 (100 mol/L) phosphorylation of
MAPK42/44 by ATP was prevented (Fig. 6B), and in paral-
lel [3H]-thymidine uptake was abolished (Fig. 6A). Basal
Fig. 1. Adenosine 5-triphosphate (ATP) and norepinephrine release (0 min) MAPK phosphorylation also was inhibited by
from human cortical kidney slices. There were two periods of electrical PD 98059 (100 mol/L; Fig. 6B). Data from two prelimi-field stimulation in each experiment (S1 and S2), each for one minute
nary experiments in whole human renal cortex showedat 20 Hz. (A) Release of endogenous ATP (N  21). (B) Release of
endogenous norepinephrine (N  21). Data are means 	 SEM. that electrical stimulation at 5 Hz and ATP (100 mol/L)
induced an activation of the MAPK42/44 pathway within 10
minutes to 159% (N 2) and 133% (N 2), respectively.
2A), whereas the norepinephrine release was slightly but RT-PCR of P2X and P2Y receptors
not significantly enhanced (Fig. 2B).
Under the conditions used significant mRNA levels
were found in vGEC for P2X4,5,6,7 and P2Y1,2,4,6,11 receptorsATP release stimulated by -adrenergic agonists in
(Fig. 8), but not for P2X1,2,3 and P2Y12 receptors (Figs. 8human kidney cortex
and 9). mRNA expression of the recently cloned P2Y12The selective 2-adrenergic agonist UK 14304 (1 receptor [18, 19] was shown in human lymphocytes dem-
mol/L) potently stimulated ATP release and this effect onstrating the ability of the primers to amplify a P2Y12was blocked by rauwolscine (0.1 mol/L; Fig. 3A) but sequence (Fig. 9). Experiments without reverse tran-
not by prazosin (0.3 mol/L; data not shown). The selec- scriptase () confirmed that the PCR products origi-
tive 1-adrenergic agonist methoxamine (10 mol/L) nated from mRNA but not from genomic DNA.
stimulated ATP release (Fig. 3B), but this effect was
much smaller than that of UK 14304. The effect of meth-
DISCUSSIONoxamine was inhibited by prazosin (0.3 mol/L).
The kidney is densely innervated by the sympathetic
Nucleotide-induced [3H]-thymidine uptake human nervous system [20] and the renal nerves control sodium
glomerular epithelial cells (vGEC) in culture reabsorption, renin secretion and renal blood flow by
In human vGEC ATP (1 to 100 mol/L), adenosine releasing norepinephrine, which activates adrenergic re-
diphosphate-S (ADPS; 1 to 100 mol/L), ADP (1 to ceptors on vascular, tubular and glomerular structures
100 mol/L) and ATPS (1 to 100 mol/L) increased of the kidney [5]. Moreover, -adrenergic receptors are
[3H]-thymidine uptake in a concentration dependent involved in proliferative processes in renal cells [21, 22].
manner (Fig. 4). ATP, ATPS and ADP were about In accord with these findings, in an animal model of
equally potent and effective. ADPS induced a smaller chronic renal failure with elevated sympathetic tone, we
recently showed that the sympatholytic drug moxonidineresponse at the concentration of 100 mol/L. Uridine
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Fig. 2. Effects of tetrodotoxin (TTX) and complete -adrenergic blockade on ATP and norepinephrine (NE) release from human cortical kidney
slices. There were two periods of electrical field stimulation in each experiment (S1 and S2), each for one minute at 20 Hz. Drugs were added 15
minutes before S2. (A) Control (N  21), TTX (N  4), prazosin (PRA)/rauwolscine (RAU) (N  9). (B) Control (N  21), TTX (N  4), PRA/
RAU (N  8). Data are means 	 SEM. * Significant differences from control by the Student t test (P 
 0.05).
and the -blocker metoprolol reduced renal damage in- trical stimulation-induced ATP release was reduced by
75%. For unknown reasons only a non-significant in-dependently from influences on blood pressure [6, 8]. In
addition to norepinephrine ATP is released as a cotrans- crease of norepinephrine release in the presence of the
prazosin/rauwolscine combination was observed, in con-mitter in many sympathetically innervated organs [23].
Our current study demonstrates the neuronal and non- trast to previous results [27]. The inhibitory effect of
complete -adrenoceptor blockade on the electrically-neuronal release of ATP in human renal cortex and
describes the mechanisms by which ATP has mitogenic induced ATP release suggests that neuronally released
norepinephrine activates -adrenoceptors on renal corti-effects in human visceral glomerular epithelial cells
(vGEC) used as a model for cells involved in progression cal cells to release ATP. On the other hand, 25% of
the electrically-induced ATP release were resistant toof proteinuric renal disease.
-adrenoceptor blockade and, therefore, are most likely
ATP release in human kidney cortex of neuronal origin. This confirms the role of ATP as
a neurotransmitter in the human kidney. -AdrenergicElectrical field stimulation of superfused human corti-
cal kidney slices induced concomitant release of ATP receptors are divided into 1- and 2-subtypes [28], which
are both activated by norepinephrine. Both subtypesand norepinephrine. Electrically induced ATP and nor-
epinephrine release was prevented by the sodium chan- have been found in human kidney by pharmacological
and molecular techniques, although the evidence for ex-nel blocker tetrodotoxin, suggesting a neuronal source
of both neurotransmitters. However, in several isolated pression at the protein level is most convincing for
2-adrenergic receptors [29]. To characterize the recep-tissues [24, 25] including the rat kidney [10], ATP release
from non-neuronal cells due to activation of -adrener- tor subtype mediating non-neuronal ATP release in hu-
man renal cortex, we mimicked the effects of endogenousgic receptors by endogenous norepinephrine has been
demonstrated. To elucidate the relationship between norepinephrine by the use of selective agonists. Both the
2-agonist UK 14304 and the 1-agonist methoxamineneuronal and non-neuronal origin of the ATP release by
sympathetic nerve stimulation, we eliminated the effects induced the release of ATP from human cortical kidney
slices, but the effect of the 2-agonist was much moreof endogenous norepinephrine by complete-adrenergic
blockade using a combination of prazosin and rauwols- pronounced. Previous studies on isolated blood vessel
or the vas deferens showed that the effect of endogenouscine. This combination totally eliminates all -adrenergic
effects of norepinephrine [26]. In this situation, the elec- norepinephrine on ATP release is mainly mediated by
Vonend et al: ATP release in human kidney1622
Fig. 3. -Adrenergic agonist-induced ATP
release from human cortical kidney slices. (A)
Effect of the 2-selective agonist UK 14304 in
the absence (N  20, control N  15) and
presence of rauwolscine (RAU; N  10, con-
trol N  5). (B) Effect of the 1-selective
agonist methoxamine (MET) in the absence
(N  20, control N  15) and presence of
prazosin (PRA; N  9, control N  7). Data
are means 	 SEM. * Significant differences
from control by the Student t test (P 
 0.05).
1-adrenergic receptors [30, 31]. In contrast, in human lial cells, which have been shown to release ATP after
mechanical stress [34].renal cortex 2-adrenergic receptors apparently play a
dominant role. At present, for the kidney the source of
ATP and DNA synthesis in human renal
non-neuronal -adrenoceptor-stimulated ATP release is cells in culture
not known.2-Adrenergic receptors also appear to domi-
After demonstrating the release of ATP, we examinednate the regulation of renal blood flow in humans [32, 33].
its potential role to act as mitogenic factor in vGEC cells,Thus, it seems to be possible that the 2-receptor medi- since these cells are known to be altered in chronic renal
ated vasoconstriction of cortical blood vessels induced failure [6, 16]. Physiological and pathophysiological ef-
the release of ATP in the kidney slices. The higher ex- fects of ATP are mediated by P2-receptors, which are di-
pression levels of 2-adrenergic receptors then would be vided into two classes: P2Y-receptors coupled to G-pro-
the reason for the more pronounced effect of 2-receptor teins and P2X-receptors representing ligand-gated ion
activation on ATP release. ATP release due to 2-recep- channels. ATP induced stimulation of DNA synthesis
was the consequence of P2-receptor activation as showntor mediated vasoconstriction also may involve endothe-
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Fig. 4. Effects of various nucleotides on [3H]-
thymidine uptake in visceral glomerular epi-
thelial cells (vGECs). All experiments were
performed under growth-arrested conditions.
Substances were present for 24 hours, and cells
were incubated with [3H]-thymidine during
the last 6 hours. An increase in the concentra-
tion of fetal calf serum (FCS) from normal
0.5% (control) to 20% caused an increase in
thymidine uptake. Data are means 	 SEM of
4 to 12 experiments for each concentration
of nucleotides. * Significant differences from
control by the Student t test (P 
 0.05).
P2X4,6,7 and P2Y4 receptors [38–41]. The effect of ATP on
[3H]-thymidine uptake in vGEC observed in the present
study was mimicked by ATPS and the preferential
P2Y1,12 receptor agonists ADP and ADPS, but neither
by the P2X1,3/P2X7 agonists ,-methylene-ATP and
BzATP, nor by the uracil nucleotides UTP and UDP,
which activate P2Y2, P2Y4 and P2Y6 receptors [38–42].
The adenosine diphosphate analogs ADP and ADPS
are potent agonists at cloned and expressed P2Y1 and
P2Y12 receptors, but no or only weak agonists at P2X
receptors or any of the remaining cloned mammalian
P2Y subtypes [18, 19, 38–42]. The potent action of these
diphosphate analogs on [3H]-thymidine uptake charac-
terizes the receptor involved in the mitogenic effects of
adenine nucleotides in vGEC as either P2Y1 or P2Y12
(or a yet not cloned receptor with very similar pharmaco-Fig. 5. Effect of suramin on basal and ATP-induced [3H]-thymidine
uptake in vGECs. All experiments were performed under growth- logical properties). However, the RT-PCR experiments
arrested conditions. ATP was present for 24 hours. Suramin was added clearly demonstrated the expression of only P2Y1 but notone hour before ATP. Cells were incubated with [3H]-thymidine during
P2Y12 receptors in these cells. Hence, P2Y1-like receptorsthe last 6 hours. Data are means 	 SEM of 6 to 12 experiments for
each concentration of ATP. * Significant differences from control by mediate at least a substantial part of mitogenic effects
the Student t test (P
 0.05). Significant differences from the respective of adenine nucleotides such as ATP and ADP in vGEC.value in the absence of suramin (Student t test, P 
 0.05).
An additional contribution of other receptor subtypes
(such as, P2Y11 or P2X5 for which a strong mRNA expres-
sion has been detected) cannot be excluded.
by the blockade by the P2-receptor antagonist suramin.
Activation of the mitogen-activated protein kinasesInterestingly, suramin by itself inhibited basal DNA syn-
thesis suggesting auto-stimulation by continuous release Various growth factors like PDGF or TGF- stimulate
of endogenous ATP. the extracellular signal-regulated kinase (ERK/MAPK42/44),
Which P2-receptor subtype mediates the observed mi- which appears to be a ubiquitous step for the induction
togenic effects of ATP? Effects on cell proliferation me- of cell proliferation [43]. MAPK42/44 is phosphorylated
diated by P2Y2 and/or P2Y4 receptors have been observed and activated by the MAPK kinase (MEK). In the pres-
previously in rat mesangial cells [35]. In addition, P2X ent study in vGEC, ATP and the preferential P2Y1,12-
receptor activation has been linked to proliferation at receptor agonist ADPS showed a time- and concentra-
least in human osteoblast-like cells and lymphoid cells tion-dependent activation of MAPK42/44, whereas the
transfected with the P2X7 receptor [36, 37]. Suramin at P2X1,3 selective agonist ,-methylene ATP failed to do
the concentration used (30 mol/L) blocks most of the so. The MEK inhibitor PD 98059 prevented ATP medi-
ated phosphorylation of MAPK42/44 and in parallel blockedknown mammalian P2-receptor types excluding only
Fig. 6. Effects of ATP on [3H]-thymidine
uptake and MAPk activation in vGECs. (A)
Effect of the MEK inhibitor PD 98059 on
ATP-induced [3H]-thymidine uptake. Data are
means	 SEM of 4 to 5 experiments. * Signifi-
cant difference from control (Student t test,
P 
 0.05). (B) Representative Western blot
of MAPK activation by ATP in the presence
and absence of PD 98059 ( 3).
Fig. 7. Representative time courses from three to six experiments of
adenine nucleotide-induced MAPK activation. Symbols are: () ATP
100 mol/L; () ADPS 100 mol/L; ( ) ,-mATP 100 mol/L.
Fig. 8. P2Y1,2,4,6,11 and P2X1-7 receptor subtype expression in human
vGECs analyzed by RT-PCR. PCR with reverse transcriptase ()
showed mRNA encoding for P2Y1,2,4,6,11 and P2X4-7. Weight marker is
100 bp. PCR without RT () showed no amplification products.
the ATP induced increase of [3H]-thymidine uptake in
human vGEC cells. To link these mitogenic effects of
ATP in vGEC with adrenergic stimulation-induced re-
lease of ATP, preliminary experiments were performed
in whole tissue. In human renal cortex both electrical
stimulation at 5 Hz and ATP induced activation of
MAPK42/44. Thus, ATP may contribute to the cell prolifer-
ative processes in chronic renal failure acting via the
MAPK42/44 pathway. Consistent with this conclusion, mi-
togenic signaling of adenine nucleotides via P2Y-recep-
tors has been recently linked in cells from several distinct
tissues to the extracellular signal-regulated kinase path-
way [44–46].
CONCLUSION
Chronic renal failure is a clinical condition character-
ized by an elevated sympathetic tone. Extracellular ATP
released upon -adrenergic receptor activation either as
Fig. 9. P2Y12 receptor subtype expression in human vGEC and ina sympathetic renal neurotransmitter or in a paracrine
human lymphocytes analyzed by RT-PCR. PCR was with RT () and
fashion, has the potential to contribute to proliferative as a negative control without RT () running along weight marker
(100 bp).processes responsible for progression in chronic renal
Vonend et al: ATP release in human kidney 1625
18. Hollopeter G, Jantzen HM, Vincent D, et al: Identification of thefailure. Therefore, ATP receptor antagonists should be
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explored to prevent progression of chronic renal diseases 40:202–207, 2001
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